• BG Medicine

  Participated · Series D · Jul 2008

  BG Medicine is a life sciences company based in Waltham, Massachusetts focused on the discovery, development, and commercialization of novel biomarker-based diagnostics. The company recently launched the BGM Galectin-3 test for use in patients with heart failure. It also has products in development to aid in the diagnosis and management of acute atherothrombosis and lipid disorders. To support commercialization efforts and provide additional growth capital, BG Medicine secured a $15 million multi-draw senior secured term loan facility agented by GE Capital, Healthcare Financial Services. Company management said GE Capital was a trusted source of financing and structured a loan well-suited to further product development and commercialization plans. GE Capital's Healthcare Financial Services group has provided more than $60 billion in financing over ten years across healthcare sectors. BG Medicine develops molecular diagnostic tests built on a patented biomarker discovery platform that integrates measurement and analysis of proteins and metabolites. The company’s tests are intended to predict drug response, assess toxicity risk, identify or prognose disease, and monitor disease progression or therapy response. BG Medicine has a pipeline focused on cardiovascular disease, cancer and central nervous system disorders and ongoing joint initiatives with Merck, AstraZeneca, Abbott, Takeda, Humana, Philips and the U.S. FDA. The firm applies systems biology to discover and validate biomarkers and has created multiple product candidates from those efforts. Proceeds from the recent financing are planned to accelerate commercialization and the launch of the company’s first two diagnostic products and to continue discovery and development of additional candidates.

• Sermo

  Participated · Series C · Oct 2007

  Sermo is a Cambridge, MA-based online physician community founded in 2005 by CEO Daniel Palestrant. The company operates a platform that allows clients to aggregate information, tap into peer-to-peer insight, gain market intelligence and increase brand awareness. Sermo has developed research platforms that enable clients to conduct real-time qualitative and quantitative research. It currently services over 300 clients, including pharmaceutical companies, healthcare institutions, financial services firms and government agencies. The company recently secured a $5M debt facility and intends to use the proceeds to continue expanding its physician community. Sermo operates an invitation‑only social network whose membership is comprised primarily of licensed physicians and which validates physician credentials. The platform gives physicians access to clinical information and lets them earn money by writing or voting for postings; the company says physician opinions on the site do not constitute malpractice. Sermo recently partnered with Pfizer to provide physicians easier access to Pfizer’s clinical information. The company is based in Cambridge, Mass., and has about 26,000 licensed physicians participating. Sermo raised $27 million in a Series C funding round last month and has to date raised $39.5 million; it will use the funding to hire more employees and increase website capacity, planning to add 25–50 employees in 2008. The U.S. FDA Center for Devices and Radiological Health also has access to the social network.

No current team members are available.